March 2017

Record Number of Abstracts Submitted for the 2017 SMA Researcher Meeting

Leave a Comment / Conference, Front Page News, Research /

Abstract submission is now closed for the 2017 SMA Researcher Meeting. We are excited to announce that we received 125 submissions, a record number. Our submissions come from researchers in 14 countries, 10 companies, and close to 50 institutions. We expect over 300 researchers and clinicians from almost 100 organizations will attend the SMA Researcher […]

Record Number of Abstracts Submitted for the 2017 SMA Researcher Meeting Read More »

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA

Leave a Comment / Clinical Trials, Front Page News /

Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open to enrollment. This clinical trial is designed to assess the effect of CK-2127107, a next-generation fast skeletal troponin activator (FSTA), on multiple measures of muscle function in both ambulatory and

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA Read More »

Cure SMA Coverage and Payment Policy Project Continues to Move Forward

Leave a Comment / Advocacy, Front Page News /

The Cure SMA Coverage and Payment Policy Project has two distinct but complementary tracks: Outreach on behalf of our community. We’re working with public and private insurers, regulators, and other stakeholders, advocating for prompt, comprehensive coverage for SMA treatments and care.  Outreach to our community. We’re working to provide the necessary tools and information so

Cure SMA Coverage and Payment Policy Project Continues to Move Forward Read More »

Genentech Roche Releases Community Letter with Clinical Trial Updates

Leave a Comment / Clinical Trials, Front Page News /

Genentech Roche provided the following community statement with clinical trial updates for SUNFISH (Type 2/3), FIREFISH (Type 1) and JEWELFISH. Dear SMA community, At Genentech (A Member of the Roche Group) we are committed to addressing the urgent needs of people living with SMA. We are happy to share this update on our two investigational

Genentech Roche Releases Community Letter with Clinical Trial Updates Read More »

Cure SMA Releases Schedule for the 2017 Annual SMA Conference

Leave a Comment / Conference, Front Page News /

Cure SMA has released the schedule for the 2017 Annual SMA Conference, to be held at Walt Disney World in Orlando, FL, June 29 – July 2. The schedule includes the timeline of workshops and events, including the Meet and Greet, Researcher Relay Race, Teen Social, Newly Diagnosed Program, Family Friendly Poster Session, PJ Party

Cure SMA Releases Schedule for the 2017 Annual SMA Conference Read More »

Cure SMA Awards $140,000 Grant to Joceyln C̫t̩, PhD, University of Ottawa

Leave a Comment / Front Page News, Research /

Cure SMA has awarded a $140,000 research grant to Joceyln Côté, PhD, at The University of Ottawa, for his project, “Investigating the mechanism by which SMN regulates translation: identification of novel therapeutic targets.” Understanding the function of the SMN protein is vital to understanding SMA and serves to aid in the development of therapeutics. In

Cure SMA Awards $140,000 Grant to Joceyln C̫t̩, PhD, University of Ottawa Read More »

American College of Obstetricians and Gynecologists Recommends Expanded SMA Carrier Screening

Leave a Comment / Front Page News, Support & Care /

The American College of Obstetricians and Gynecologists has released updated guidance on carrier testing for genetic conditions. The updated guidance includes, for the first time, a recommendation that all women who are pregnant or considering pregnancy be screened for spinal muscular atrophy. Previously, carrier screening was only recommended for women with a known family history

American College of Obstetricians and Gynecologists Recommends Expanded SMA Carrier Screening Read More »

AveXis Reports Results from Phase 1 Trial of AVXS-101

Leave a Comment / Clinical Trials, Front Page News /

AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. The company also reported financial results for the fourth quarter and full year ended December 31, 2016, recent

AveXis Reports Results from Phase 1 Trial of AVXS-101 Read More »

Know Your Resources: How Congressional Caseworkers Can Help You Obtain Insurance Coverage for New Therapies

Leave a Comment / Advocacy, Community Awareness, Front Page News /

Your elected officials who represent you in Washington, D.C. have caseworkers in their regional and district offices in your communities. These caseworkers can help you work with and better understand government programs, like Medicaid, Medicare, TRICARE, and Social Security. Caseworkers, also sometimes called constituent services representatives, are in the local community offices of federal elected

Know Your Resources: How Congressional Caseworkers Can Help You Obtain Insurance Coverage for New Therapies Read More »

Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University

Leave a Comment / Front Page News, Our Impact, Research /

Cure SMA has awarded a $140,000 research grant to Arthur Burghes, PhD, at The Ohio State University, for his project, “Identification of SMA modifiers and deletion/duplication junctions in the SMA region.” All individuals with SMA lack the SMN1 gene, but have one or more copies of SMN2, the SMA “backup gene.” In general, those with

Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University Read More »

Scroll to Top